In Japan, among these biomarkers, measurement of urinary L-type fatty acid-binding protein (L-FABP) and NGAL is covered by insurance for patients with suspected AKI, while measurement of kidney injury molecule-1 (KIM-1), and NephroCheck® (urinary tissue inhibitor of metalloproteinase 2 multiplied by insulin-like growth factor-binding protein 7 concentration) are not. Here, FABP1 is linked to acute kidney injury.